Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
New breast cancer study findings have been reported by researchers at Medical University of Vienna
March 12th, 2009
" Ovarian suppression plus tamoxifen is a standard adjuvant treatment in premenopausal women with endocrine- responsive breast cancer. Aromatase inhibitors are superior to tamoxifen in postmenopausal patients, and preclinical data suggest that zoledronic acid has antitumor properties," investigators in Vienna, Austria report. " We examined the effect of adding zoledronic acid to a combination of either goserelin and tamoxifen or goserelin and anastrozole in premenopausal women with endocrineresponsive early breast cancer. We randomly assigned 1803 patients to receive goserelin ( 3.6 mg given subcutaneously every 28 days) plus tamoxifen ( 20 mg per day given orally) or...
Source: Women's Health Weekly (2009-03-12)
|
